The Combined Inhibition of <scp>SREBP</scp> and <scp>mTORC1</scp> Signaling Synergistically Inhibits B‐Cell Lymphoma
These results highlight the potential of a combined therapeutic approach targeting both SREBP and mTORC1 as a novel strategy for treating B-cell lymphoma.
Authors
- Zhenglun Zhu (ORCID: https://orcid.org/0000-0003-4533-1893)
- Jiehao Zhou (ORCID: https://orcid.org/0000-0003-3576-5591)
- Wenxia Jiang (ORCID: https://orcid.org/0000-0003-2307-5091)
- Alexander R. Maldeney
- Wei Luo (ORCID: https://orcid.org/0000-0003-2826-1723)
- Jing Yang (ORCID: https://orcid.org/0000-0002-4983-1660)
- Jingru Liang (ORCID: https://orcid.org/0000-0002-2423-0666)
Institutions
- Indiana University Health (US)
- Mayo Clinic in Florida (US)
- Indiana University School of Medicine
- Indiana University – Purdue University Indianapolis (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1002/cam4.70342
- Citations
- 5
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.43
Funders
- American Cancer Society
- Ralph W. and Grace M. Showalter Research Trust Fund
- School of Medicine, Indiana University